Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00792701 · ClinicalTrials.gov registry record · Phase 2

S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer

A Phase 2 study of Lung Cancer, sponsored by SWOG Cancer Research Network.

Completed
Registry status
Phase 2
Development phase
85
Enrollment target
20
Study locations

NCT00792701 is a Phase 2 study of Lung Cancer that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 85 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00792701, a Phase 2 study of Lung Cancer, has completed, sponsored by SWOG Cancer Research Network.

COMPLETED
Registry status
Phase 2
Development phase
85 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy drugs after surgery may kill any tumor cells that remain after surgery. Sometimes, after surgery, the tumor may not need more treatment until it progresses. In this case, observation may be sufficient. PURPOSE: This phase II trial is studying how well giving gemcitabine together with cisplatin works in treating patients with stage I non-small cell lung cancer that was removed by surgery.

Conditions Studied

Lung Cancer

Interventions

  • DRUG cisplatin
  • DRUG gemcitabine hydrochloride

Study Locations (20)

California

  • City of Hope Comprehensive Cancer Center - Duarte
  • Tibotec Therapeutics - Division of Ortho Biotech Products, LP - Marysville
  • Valley Medical Oncology Consultants - Pleasanton - Pleasanton
  • Sutter Cancer Center at Roseville Medical Center - Roseville
  • Sutter Cancer Center - Sacramento
  • University of California Davis Cancer Center - Sacramento
  • Tahoe Forest Cancer Center - Truckee

Illinois

  • Saint Anthony's Hospital at Saint Anthony's Health Center - Alton
  • Decatur Memorial Hospital Cancer Care Institute - Decatur
  • Sherman Hospital - Elgin
  • Regional Cancer Center at Memorial Medical Center - Springfield

Kansas

  • Cancer Center of Kansas, PA - Chanute - Chanute
  • Cancer Center of Kansas, PA - Dodge City - Dodge City
  • Cancer Center of Kansas, PA - El Dorado - El Dorado
  • Cancer Center of Kansas - Fort Scott - Fort Scott

Arkansas

  • Hembree Mercy Cancer Center at St. Edward Mercy Medical Center - Fort Smith

Connecticut

  • Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center - Hartford

Georgia

  • Northeast Georgia Medical Center - Gainesville

Hawaii

  • Tripler Army Medical Center - Honolulu

Indiana

  • St. Francis Hospital and Health Centers - Beech Grove Campus - Beech Grove

Trial Details

FieldValue
Enrollment Target 85 participants
Start Date 2008-11
Est. Completion 2016-04
Phase Phase 2

Sponsor

SWOG Cancer Research Network

270 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00792701

The ClinicalTrials.gov registry entry for NCT00792701 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (91% lower). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which cisplatin is the first listed.

NCT00792701 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Illinois, Kansas.

Frequently Asked Questions

What is clinical trial NCT00792701 about?

NCT00792701 is a clinical study titled "S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy drugs after surgery may kill any tumor cells that remain after surgery. Sometimes, af...

What is the current status of trial NCT00792701?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2008-11. Estimated completion is 2016-04.

What conditions does trial NCT00792701 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT00792701?

The interventions under investigation include: cisplatin (DRUG), gemcitabine hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00792701?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00792701 being conducted?

This trial has 20 study locations across Arkansas, California, Connecticut, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.